Protein kinase AMPK agonists or ketogenic diets promote PD-L1 phosphorylation and disrupt its interaction with CMTM4, which contributed to inducing PD-L1 degradation and enhancing anti-CTLA4 immunotherapy in mouse tumor models [141]. The gene discussed is CTLA4; the disease is neoplasm.